Sugi Predict

Sugi Predict / Targets / SEM1

SEM1

26S proteasome complex subunit SEM1 (26S prot · P60896 · SEM1 on Sugi Atlas →

7,511 patent compounds predicted against SEM1, 5,912 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1478606 SCHEMBL1478606 0.58 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20
SCHEMBL607553 SCHEMBL607553 0.54 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20
SCHEMBL606932 SCHEMBL606932 0.53 11/20
SCHEMBL1477893 SCHEMBL1477893 0.53 11/20
SCHEMBL608362 SCHEMBL608362 0.53 11/20
SCHEMBL608599 SCHEMBL608599 0.53 11/20
SCHEMBL1327441 SCHEMBL1327441 0.53 11/20
SCHEMBL605129 SCHEMBL605129 0.52 11/20
SCHEMBL608009 SCHEMBL608009 0.52 11/20
SCHEMBL1478157 SCHEMBL1478157 0.52 11/20
SCHEMBL609081 SCHEMBL609081 0.52 11/20
SCHEMBL606926 SCHEMBL606926 0.52 11/20

Clinical trials — most relevant to SEM1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance PHASE2WITHDRAWN
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis PHASE1WITHDRAWN
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies nanUNKNOWN
Shwachman Diamond Syndrome Registry and Study nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SEM1 binder may also engage these)

ProteinNameSimilarity
Q3ZBR6 — 1.000 Q3ZBR6 →
P60897 — 1.000 P60897 →
Q9XIR8 — 0.985 Q9XIR8 →
Q9FL96 — 0.983 Q9FL96 →
Q9VM46 — 0.979 Q9VM46 →
Q7SA04 — 0.973 Q7SA04 →
O14140 — 0.966 O14140 →
A8XLU5 — 0.961 A8XLU5 →
P62499 — 0.960 P62499 →
Q95Y72 — 0.954 Q95Y72 →
O94742 — 0.953 O94742 →
CLTA Clathrin light chain A 0.947 landscape →
CLTB Clathrin light chain B 0.947 landscape →
Q54K21 — 0.944 Q54K21 →
Q6IRU5 — 0.944 Q6IRU5 →
P08081 — 0.944 P08081 →
P04975 — 0.944 P04975 →
P08082 — 0.944 P08082 →
O08585 — 0.944 O08585 →
Q6INR1 — 0.943 Q6INR1 →
P28656 — 0.942 P28656 →
A6H767 — 0.941 A6H767 →
P04973 — 0.941 P04973 →
Q7SXU0 — 0.941 Q7SXU0 →
Q8HXY9 — 0.941 Q8HXY9 →
Q4ADK7 — 0.940 Q4ADK7 →
Q9Z2G8 — 0.940 Q9Z2G8 →
Q28EB4 — 0.940 Q28EB4 →
Q76MT4 — 0.940 Q76MT4 →
P41236 — 0.939 P41236 →